Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Welichem Biotech's lead compound WBI-2100 has produced positive anticancer activity in a human melanoma cancer model grown in mice.
Subscribe to our email newsletter
The results from work done at the Centre of Translational Research in Cancer of the Jewish General Hospital in Montreal showed a potent delay of tumor growth following administration of WBI-2100.
The results are consistent with those from in vitro and in vivo studies on WBI-2100 conducted by the US National Cancer Institute. WBI-2100, a fully synthesized, small molecule compound, delayed the growth of common cancers such as breast, ovary and colon.
“These positive results of WBI-2100, in studies from different research laboratories are very encouraging, and the nature of the data open-up potential for use of this novel agent alone or in conjunction with existing therapies” said president and CEO Dr John Webster.
Welichem’s compounds in the WBI-2000 series are tested, under a November, 1996 screening agreement, with the Cancer Treatment and Diagnosis Division of National Cancer Institute, the principal agency for cancer research of the US government.